




Pelagia Research Library

Der Chemica Sinica, 2013, 4(4):12-16



Novel one-pot synthesis and antimicrobial activity of 7-chloro-4-phenyl-3,4-dihydro-2H-1,3-benzoxazin-2-one derivatives

Sayaji S. Didwagh and Pravina B. Piste*

P. G. Department of Chemistry, Yashwantrao Chavan Institute of Science, Satara, Maharashtra, India

ABSTRACT

A novel one-pot synthesis of 7-chloro-4-phenyl-3,4-dihydro-2H-1,3-benzoxazin-2-one derivatives [1a-1i] by condensation of a variety of aromatic aldehydes with p-chlorophenol and urea in the presence of wet cyanuric chloride under solvent free condition. All synthesized compounds were characterized on the basis of IR, NMR spectroscopic data and Elemental Analysis. All the compounds have been screened for antimicrobial activity by the cup-plate method. The results reveal that some of the synthesized 1,3-benzoxazine derivatives were exhibited good to moderate antibacterial and antifungal activity.

Keywords: Synthesis, 1,3-benzoxazin-2-one, cyanuric chloride, aldehyde, solvent free, antimicrobial activity.

INTRODUCTION

The synthesis of new analogs of bioactive heterocyclic compounds represents a major challenge in synthetic organic and medicinal chemistry [1]. Due to their wide range of biological activities. Aromatic condensed oxazinone derivatives have received considerable attention due to the attractive pharmacological properties associated with their heterocyclic scaffold [2]. Nitrogen heterocycles are of special interest because they constitute an important class of natural and nonnatural products, many of which exhibit useful biological activities [3]. Oxazine derivatives are an important class of heterocyclic compounds. They possess varied biological activities such as antimicrobial [4-9] and anticoagulant activities [10-11], anticancer [12], and analgesic, anti-inflammatory [13] antimycobacterial [14], anti-tubercular [15-18], antimalarial [19], anti-HIV [20], fungicidal [21], antibacterial [22-23], antidiabetic and hypolipidaemic [24], antiproliferative [25], Antiplatelet aggregation [26-27], Enzyme inhibitory [28-30] activities. The 1,3-oxazine nucleus features prominently in many biologically important natural products and other bioactive molecules [31]. Owing to the above facts and in continuation of our research work on novel biologically active heterocycles and their increasing importance in pharmaceutical and biological field. Therefore, we synthesized new 7-chloro-4-phenyl-3,4-dihydro-2H-1,3-benzoxazin-2-one derivatives using p-chlorophenol with various aromatic aldehydes and urea in the presence of wet cyanuric chloride under solvent free condition and screened their antimicrobial activities.


MATERIALS AND METHODS

The melting points were recorded on electro-thermal apparatus and are uncorrected. The purity of the compounds was checked by TLC on pre-coated SiO₂ gel (HF254, 200 mesh) aluminium plates (E Merck) using hexane and ethyl acetate visualized in iodine chamber. IR spectra were recorded in KBr on a Perkin-Elmer model-983. ¹H NMR

spectrum recorded on Varian Mercury 300MHz instrument using CDCl_3 , DMSO-d_6 as solvent (chemical shift in δ ppm), using TMS as internal standard. Elemental analysis was performed on a Heracus CHN analyzer and was within the $\pm 0.5\%$ of the theoretical values.

General procedure for the preparation of 7-chloro-4-phenyl-3,4-dihydro-2H-1,3-benzoxazin-2-one derivatives [1a-1i]

A mixture of P-Chlorophenol (1 mmol), aromatic aldehyde (1 mmol), urea (1mmol), TCT (0.1 mmol, 0.0184 g) and water (1-2 drops) mixed well and was heated at 100 - 150°C for an appropriate time (Table 1).. After the completion of the reaction monitored by TLC, the reaction mixture diluted with water (4-5 mL) and stirred for 5-10 minutes. The solid product was filtered and the crude product was crystallized with ethanol to afford the pure product.



Spectroscopic data of synthesized compounds [1a-1i] :

7-chloro-4-phenyl-3,4-dihydro-2H-1,3-benzoxazin-2-one [1a]

M.F= $\text{C}_{14}\text{H}_{10}\text{ClNO}_2$; M.W=257.6; IR (KBr, cm^{-1}): 3345(N-H), 2930(C-H), 1695 (C=O), 1633, 1456 (C=C), 1171(C-O), 775(C-Cl); ^1H NMR(300MHz, CDCl_3 , DMSO-d_6 , ppm) 8.65(1H, s, NH), 6.15(1H, s, CH), 7.09-7.67 (7H, m, Ar-H).

7-chloro-4-(4-methoxyphenyl)-3,4-dihydro-2H-1,3-benzoxazin-2-one[1b]

M.F= $\text{C}_{15}\text{H}_{12}\text{ClNO}_3$; M.W= 289.6; IR(KBr, cm^{-1}): 3351 (N-H), 2927(C-H), 1692(C=O), 1635, 1451 (C=C), 1173(C-O), 775(C-Cl); ^1H NMR(300MHz, CDCl_3 , DMSO-d_6 , ppm): 8.73(1H, s, NH), 6.21(1H, s, CH, 7.12-7.79 (6H, m, Ar-H).

7-chloro-4-(4-chlorophenyl)-3,4-dihydro-2H-1,3-benzoxazin-2-one [1c]

M.F= $\text{C}_{14}\text{H}_9\text{Cl}_2\text{NO}_2$; M.W=294.1; IR(KBr, cm^{-1}): 3353 (N-H), 2931(C-H), 1693(C=O), 1633, 1451 (C=C), 1173(C-O), 775(C-Cl); ^1H NMR(300MHz, CDCl_3 , DMSO-d_6 , ppm): 8.71(1H, s, NH), 6.19(1H, s, CH), 7.15-7.78 (6H, m, Ar-H).

7-chloro-4-(2-chlorophenyl)-3,4-dihydro-2H-1,3-benzoxazin-2-one [1d]

M.F= $\text{C}_{14}\text{H}_9\text{Cl}_2\text{NO}_2$; M.W=294.1; IR(KBr, cm^{-1}): 3355 (N-H), 2933(C-H), 1696(C=O), 1637, 1453 (C=C), 1175(C-O), 775(C-Cl); ^1H NMR(300MHz, CDCl_3 , DMSO-d_6 , ppm): 8.71(1H, s, NH), 6.27(1H, s, CH), 7.12-7.77 (6H, m, Ar-H).

7-chloro-4-(4-hydroxyphenyl)-3,4-dihydro-2H-1,3-benzoxazin-2-one [1e]

M.F= $\text{C}_{14}\text{H}_{10}\text{ClNO}_3$; M.W=273.5; IR(KBr, cm^{-1}): 3327 (N-H), 2930(C-H), 1695(C=O), 1633, 1457 (C=C), 1172(C-O), 775(C-Cl); ^1H NMR(300MHz, CDCl_3 , DMSO-d_6 , ppm): 8.69(1H, s, NH), 6.23(1H, s, CH), 7.13-7.75 (6H, m, Ar-H).

7-chloro-4-[4-(dimethylamino)phenyl]-3,4-dihydro-2H-1,3-benzoxazin-2-one [1f]

M.F= $\text{C}_{16}\text{H}_{15}\text{ClN}_2\text{O}_2$; M.W=302.7; IR(KBr, cm^{-1}): 3335(N-H), 2937(C-H), 1685(C=O), 1639, 1451 (C=C), 1171(C-O), 775(C-Cl); ^1H NMR(300MHz, CDCl_3 , DMSO-d_6 , ppm): 8.67(1H, s, NH), 6.21(1H, s, CH), 7.11-7.73 (6H, m, Ar-H).

7-chloro-4-(4-nitrophenyl)-3,4-dihydro-2H-1,3-benzoxazin-2-one [1g]

M.F=C₁₄H₉ClN₂O₄; M.W=304.6; IR (KBr, cm⁻¹): 3349 (N-H), 2934(C-H), 1689(C=O), 1635, 1449 (C=C), 1173(C-O), 775(C-Cl); ¹HNMR(300MHz, CDCl₃, DMSO-d₆, ppm): 8.69(1H, s, NH), 6.19(1H, s, CH), 7.15-7.79 (6H, m, Ar-H).

7-chloro-4-(3-nitrophenyl)-3,4-dihydro-2H-1,3-benzoxazin-2-one[1h]

M.F=C₁₄H₉ClN₂O₄; M.W=304.6; IR(KBr, cm⁻¹): 3357 (N-H), 1698(C=O), 1635, 1459 (C=C), 1177(C-O), 776(C-Cl); ¹HNMR(300MHz, CDCl₃, DMSO-d₆, ppm): 8.71(1H, s, NH), 6.23(1H, s, CH), 7.19-7.81 (6H, m, Ar-H).

7-chloro-4-(4-methylphenyl)-3,4-dihydro-2H-1,3-benzoxazin-2-one[1i]

M.F=C₁₅H₁₂ClNO₂; M.W=271.7; IR (KBr, cm⁻¹): 3345 (N-H), 2933 (C-H), 1687(C=O), 1633, 1451 (C=C), 1171(C-O), 775(C-Cl); ¹HNMR (300MHz, CDCl₃, DMSO-d₆, ppm): 8.67(1H, s, NH), 6.17(1H, s, CH), 7.11-7.76 (6H, m, Ar-H).

Table No. 1: Physical and Elemental analysis of Synthesized compounds(1a-1i):

Comp No	R1	Time (min)	M.P. °C	Yield %	Elemental analysis				
					%C	%H	%N	%O	%Cl
1a	C ₆ H ₅	9	161	59	64.3	3.6	4.9	12.2	13.4
1b	4-OCH ₃ C ₆ H ₄	2	175	71	62.1	3.9	4.3	16.3	12.1
1c	4- ClC ₆ H ₄	8	165	67	56.9	3.0	4.7	10.3	24.1
1d	2-ClC ₆ H ₄	11	159	69	57.1	3.0	4.6	10.5	24.1
1e	4- OHC ₆ H ₄	3	178	75	60.6	3.4	5.0	17.1	12.8
1f	4.N(CH ₃) ₂ C ₆ H ₄	5	231	67	62.8	4.3	9.1	10.3	11.6
1g	4- NO ₂ C ₆ H ₄	4	196	65	54.9	2.8	8.7	21.0	11.3
1h	3- NO ₂ C ₆ H ₄	7	191	73	55.0	2.7	8.9	20.4	11.0
1i	4-CH ₃ C ₆ H ₄	15	209	63	64.2	4.0	5.1	11.6	12.2

Antimicrobial activity:

The synthesised compounds (**1a-1i**) were screened for their in vitro antimicrobial activity by using cup plate method [32]. Antibacterial activity was screened against two gram positive bacteria *Staphylococcus aureus*, *Bacillus subtilis* and two gram negative bacteria *Escherichia coli*, *Pseudomonas aeruginosa* by measuring the zone of inhibition on agar plates at concentrations 100 µg/mL. Antifungal activity was screened against *Candida albicans*, *Aspergillus niger* by measuring the zone of inhibition on agar plates at concentrations 100 µg/mL and reported in Table-3. Nutrient agar was employed as culture medium and DMSO was used as solvent control for antimicrobial activity. Streptomycin and griseofulvin were used as standard for antibacterial and antifungal activities respectively.

RESULTS AND DISCUSSION

Benzoxazin-2-one derivatives were synthesised in moderate yields by reacting with p-chlorophenol with different aromatic aldehydes and urea in the presence of wet cyanuric chloride under solvent free condition. The structure of compounds are confirmed by IR, ¹H NMR spectroscopy. To check the applicability of the synthesized compounds, they were screened for their antibacterial and antifungal activity by using cup-plate method. The antibacterial and antifungal activity of each compound was compared with standard drug Streptomycin and griseofulvin. Most of the compounds exhibited good to moderate antitibacterial and antifungal activity against the tested microorganisms. The antibacterial activity are shown in Table 2. The Compound bearing **1a** (R1 = H), **1b** (4-OCH₃), **1c** (4-Cl), **1d** (2-Cl), **1g** (4-NO₂) substituents showed good activity against gram-positive *Staphylococcus aureus*, *Bacillus subtilis* and gram-negative bacteria *Escherichia coli*, *Pseudomonas aeruginosa*. While other compounds **1e** (4-OH), **1f** (4-N(CH₃)₂), **1h** (2-NO₂) **1i** (4-CH₃) exhibited moderate to poor activity as compared to standard drug. The antifungal activity are shown in Table 2. The Compounds bearing **1a** (R1 = H), **1b** (R =4-OCH₃), **1c** (4-Cl), **1d** (2-Cl), **1e** (4-OH), **1g** (4-NO₂), **1h** (2-NO₂) substituents showed good activity against *Candida albican*, *Aspergillus niger*. while The remaining compounds **1f** (4-N(CH₃)₂), **1i** (4-CH₃) exhibited moderate to poor activity as compared to standard drug Streptomycin and griseofulvin. As we consider all results obtained from antibacterial and antifungal tests together we can say that entire compounds tested are active towards bacteria and fungi.

Table No. 2 : Antimicrobial activity of Synthesized Compounds

Comp. (100µg/ml)	Antibacterial				Antifungal	
	S. <i>Aureus</i>	B. <i>Subtilis</i>	E. <i>Coli</i>	P. <i>aeruginosa</i>	C. <i>albicans</i>	A. <i>niger</i>
1a	13	15	17	12	15	12
1b	12	17	15	18	19	14
1c	17	19	20	15	20	17
1d	16	17	19	17	19	13
1e	04	09	06	03	14	15
1f	05	03	10	09	07	09
1g	13	20	17	15	17	17
1h	06	05	03	10	16	12
1i	04	09	06	07	08	05
Streptomycin	17	20	22	19	-	-
Griesofulvin	-	-	-	-	21	17

CONCLUSION

The synthetic procedure to get series of 7-chloro - 4 - phenyl - 3,4 - dihydro-2H- 1,3 - benzoxazin- 2- one derivatives **[1a -1i]** from P-Chlorophenol and substituted aromatic aldehyde and urea in the presence of wet cyanuric chloride under solvent free condition. Moderate yields, easy work up, short reaction times and avoiding the use of organic solvent. The newly synthesized compounds were confirmed by the spectral analysis and further evaluated for their antimicrobial activities against various types of bacteria and fungi. Some of the compounds of the series exhibited promising antibacterial and antifungal activity compared to standard drugs.

Acknowledgement

We are very thankful to the Head Department of Chemistry, Principal Y.C.I.S. Satara for providing laboratory Facilities and Shivaji University Kolhapur, National Chemical Laboratory Pune, for providing necessary instrumental facilities

REFERENCES

- [1] A. S. Girgis, *Pharmazie.*, **2000**, 426.
- [2] A. Kumer, A. Saxena, M. Dewan, D. De, S. Mozumdar, *Tetrahedron Letters.*, **2011**, 52: 4835-4839.
- [3] Z. Turgut , E. Pelit, A. Koycii, *Molecules.*, **2007**, 12: 345-352.
- [4] B.P. Mathew, A. Kumar, S. Sharma, P. Shukla, M. Nath ,*Eur.J.Med Chem.*, **2010**, 45: 1502-1507.
- [5] S. Ozden, A. Ozturk, H. Goker, N. Altanlar, *IL Farmac.*, **2000**, 55: 715-718.
- [6] R. Fringuelli, D. Pietrella , F. Schiaffella, A. Guarraci , S. Perito, F. Bistoni, A. Vecchiarilli, *Boorg. Med. Chem.*, **2002**, 10: 1681-1686.
- [7] S. Alper-Hayta, E. Aki-Sener, B. Tekiner-Gulbas, I. Yildiz, I. Yalcin, N. Alanlar, *Eur.J.Med. Chem.*, **2006**, 41: 1398-1404.
- [8] B.P. Mathew, A. Kumar, S. Sharma, P.K. Shukla, M. Nath, *Eur. J. Med. Chem.*, **2010**, 45(15) :1502-1507
- [9] R. Sawant, L. Bhangale, J. Wadekar, P. Gaikwad, *Farmacia.*, **2012**, 60: 32-39.
- [10] R. L. Sawant , M. S. Mhaske, J. B. Wadekar, *Int J Pharm Pharm Sci.*, **2012**, 4(4): 320-323
- [11] B.L.Henry, U.R Desai, *Med Chem.*, **2008**, 6: 323-336.
- [12] M. Oubrai, C. Asche, D. Carrez, A. Croisy, P. Dumy, M. Demeunynck, *Bioorg.Med.Chem. Lett.*, **2006**, 16: 4641-4643.
- [13] B. Nora, N.K. Bellara, Y. Bentarzi ,L. Hammal, A. Geronikaki, P. Eleftherioub, A. Leguninic, *Bioorg. Med. Chem.*, 2008, 16: 3059-3066.
- [14] K. Waissner, J. Gregor, L. Kubicova, V. Klimesova, J. Kunes, M. Machacek, J. Kaustova. *Eur. J.Med. Chem.*, **2000**, 35: 733-741.
- [15] X. Li, U.H. Manjunatha, M.B. Goodwin, J.E. Knox, C.A. Lipinski, T.H. Keller, C.E. Barry, C. S. Dowd , *Bioorg Med Chem Lett.*, **2008**, 18: 2256-2262
- [16] R.F. Anderson, S.S. Shinde, A. Maroz, M. Boyd, B.D. Palmer, W.A. Denny, *Org. Biomol. Chem.*, **2008**, 6: 1973-1980.
- [17] A. M. Thompson, A. Blaser, R. F. Anderson, S.S. Shinde, S. G. Franzblau, W. A. Denny, B. D. Palmer, *J. Med. Chem.*, **2009**, 52: 637-645.

- [18] U.H. Manjunatha, H. Boshoff, C.S Dowd, L. Zhang, T.JAlbert, J.E. Norton, L. Daniels, T. Dick, S.S. Pang, C.E. Barry, *Proc. Natl. Acad. Sci. U.S.A.*, **2006**, 103: 431–436.
- [19] H. Ren, S. Grady, D. Gamenara, H. Heinzen, P. Moyna, S. L.Croft, H. Kendrick, V.Yardley G. Moyna, *Bioorg. Med. Chem. Lett.*, **2001**, 11: 1851–1854.
- [20] A.J.Cocuzza, D.R. Chidester, B.C. Cordova, S.Jeffrey, R.L.Parsons, L.T Bachelier, S.Erickson -Viitanen, G.L Trainor, S. S. Ko, *Bioorg. Med. Chem. Lett.*, **2001**, 11: 1177.
- [21] Z. Tang, Z. Zhu, Z. Xia, H. Liu, J. Chen, W. Xiao, X. Ou, *Molecules.*, **2012**, 17: 8174- 8185.
- [22] M.S. Al-Ajely, H. A. Busheer, A. Abdul Ghnni, *National J. Chem.*, **2007**, 26: 348-356.
- [23] D. Prasad, R.K. Rohilla, N. Roy, M. Nath, *Indian. J. Chem.*, **2012**, 51: 739-745.
- [24] G.R Madhavan, R. Chakabarti, K.A. Reddy, P.B. Rao, R. Rajagopalan, Iqbal, *Bioorg. Med. Chem.*, **2006**, 14: 584-591
- [25] M. Ilic, J. Ilas, S. Liekens, P. Matyus, D. Kikelja, *ARKIVOC.*, **2011** (x) 309-322.
- [26] P. Hsieh, F Chong, C Chang, F Zheng, K.H. Lin. *Bioorg. Med. Chem. Lett.*, **2004**, 14: 4751-4754.
- [27] K.M. Pritchard, J.A. Rawi, C. Bradley, *Eur. J. Med. Chem.*, **2007**, 42: 1200-1210.
- [28] U. Neumann, N. Schechter, M. Gutschow, *Bioorg. Med. Chem.*, **2001**, 9: 947-954.
- [29] E. Colson, J. Wallach, M. Hauteville, *Biochimie.*, **2005**, 87: 223-230.
- [30] A. Arcadi, C. Asti, L. Brandolini, G. Caseilli, F. Marinelli, V. Ruggieri, *Bioorg. Med. Chem. Lett.*, **2009**, 9: 1291-1294.
- [31] L.S. Yadav, V.P. Srivastava, V.K. Rai, R. Patel. *Tetrahedron.*, **2008**, 64: 4246-4253.
- [32] M. Shiradkar, R. Kale, B. Baviskar, R. Dighe. *Asian. J. Chem.*, **2007**, 19: 449.